What it's for (Indications)
- Paroxetine, exemplified by formulations such as Paraxyl CR 12.
- 5mg, is a potent selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of a range of psychiatric disorders.
- Its primary indications include Major Depressive Disorder (MDD) in adults, where it helps alleviate symptoms of low mood, anhedonia, and other vegetative symptoms.
- Furthermore, paroxetine is widely used in the management of Panic Disorder, with or without agoraphobia, effectively reducing the frequency and severity of panic attacks.
- It is also approved for the treatment of Obsessive-Compulsive Disorder (OCD), decreasing the intensity of obsessions and compulsions that significantly impair daily functioning.
- Generalized Anxiety Disorder (GAD) is another key indication, providing relief from chronic, excessive worry and associated somatic symptoms.
- Social Anxiety Disorder (SAD), also known as social phobia, responds well to paroxetine, improving fear and avoidance in social situations.
- Lastly, paroxetine is indicated for the treatment of Post-Traumatic Stress Disorder (PTSD), mitigating symptoms such as intrusive thoughts, avoidance behaviors, and hyperarousal following traumatic events.
- The controlled-release (CR) formulation is specifically designed to provide a smoother pharmacokinetic profile, which may improve tolerability for some patients.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of paroxetine, including controlled-release formulations like Paraxyl CR 12.5mg, must be individualized and titrated carefully to achieve optimal therapeutic effect while minimizing adverse reactions. For Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD), the usual starting dose for controlled-release paroxetine is typically 12.5mg once daily, often administered in the morning. The dose may be gradually increased in increments of 12.5mg at weekly intervals, based on clinical response and tolerability, with a maximum recommended dose generally not exceeding 62.5mg per day for CR formulations. For Panic Disorder and Social Anxiety Disorder (SAD), a common starting dose is also 12.5mg daily, titrating upwards as needed. For Obsessive-Compulsive Disorder (OCD) and Post-Traumatic Stress Disorder (PTSD), higher doses may be required, often starting at 12.5mg and increasing to a target range that could extend to the maximum permissible dose. It is crucial to swallow the tablet whole and not chew or crush it, as this would compromise the controlled-release properties. Dosage adjustments may be necessary in patients with renal or hepatic impairment, and elderly patients may require lower starting doses and slower titration schedules due to altered drug metabolism and excretion. Abrupt discontinuation of paroxetine should be avoided due to the risk of withdrawal symptoms; rather, the dose should be tapered gradually under medical supervision. |
Safety & Warnings
Common Side Effects
- Paroxetine, while effective, is associated with a range of potential side effects, often varying in incidence and severity.
- Common adverse reactions, particularly during the initial phase of treatment or following dose increases, include gastrointestinal disturbances such as nausea, diarrhea, constipation, and dry mouth.
- Central nervous system effects may manifest as somnolence, insomnia, dizziness, headache, and asthenia (weakness).
- Sexual dysfunction is a frequently reported side effect in both men and women, encompassing decreased libido, delayed ejaculation, anorgasmia, and erectile dysfunction.
- Other potential side effects include sweating, tremor, nervousness, and blurred vision.
- In some instances, weight gain has been observed with long-term use.
- Less common but more serious side effects can include serotonin syndrome, especially when co-administered with other serotonergic agents, which presents with mental status changes, autonomic instability, neuromuscular abnormalities, and gastrointestinal symptoms.
- Akathisia, a feeling of inner restlessness, can also occur.
- Patients should be closely monitored for worsening depression, suicidal thoughts or behaviors, particularly in children, adolescents, and young adults (under 25 years of age) during initial treatment or dose adjustments.
- Any new or worsening psychiatric symptoms should be reported to a healthcare professional immediately.
Serious Warnings
- Black Box Warning: WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors. Paroxetine is not approved for use in pediatric patients.
- Paroxetine carries several important warnings and precautions that healthcare providers and patients must be aware of.
- A Black Box Warning highlights the increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults (up to 24 years of age) treated with antidepressants, including paroxetine, compared to placebo.
- Close monitoring for clinical worsening, suicidality, or unusual changes in behavior is essential, especially during the initial months of treatment and during dose adjustments.
- Serotonin Syndrome is a potentially life-threatening condition that can occur with SSRIs, particularly when used concomitantly with other serotonergic drugs (e.
- g.
- , triptans, fentanyl, lithium, tramadol, St.
- John’s wort) or drugs that impair serotonin metabolism (e.
- g.
- , MAOIs).
- Symptoms include mental status changes, autonomic instability, neuromuscular abnormalities, and gastrointestinal symptoms.
- Discontinuation of paroxetine and supportive care are crucial if serotonin syndrome is suspected.
- Abrupt discontinuation of paroxetine can lead to withdrawal symptoms, often referred to as antidepressant discontinuation syndrome, characterized by dizziness, sensory disturbances (e.
- g.
- , paresthesias), sleep disturbances, agitation, anxiety, nausea, and headache; therefore, gradual tapering is necessary.
- Patients with a history of seizures should use paroxetine with caution, as it can lower the seizure threshold.
- Activation of mania or hypomania can occur in a small percentage of patients with mood disorders, particularly those with undiagnosed bipolar disorder.
- Paroxetine can cause hyponatremia, especially in elderly patients, those taking diuretics, or those who are otherwise volume-depleted.
- There is also a risk of increased bleeding, particularly when co-administered with antiplatelet agents or anticoagulants, due to its effect on platelet serotonin reuptake.
- Angle-closure glaucoma risk may be increased in susceptible individuals.
- Paroxetine should be used with extreme caution in patients with uncontrolled narrow-angle glaucoma.
How it Works (Mechanism of Action)
Paroxetine, as an exemplar of the selective serotonin reuptake inhibitor (SSRI) class, exerts its primary therapeutic effects through potent and highly specific inhibition of serotonin (5-hydroxytryptamine, 5-HT) reuptake into presynaptic neurons within the central nervous system (CNS). By blocking the serotonin transporter (SERT) protein, paroxetine prevents the rapid removal of serotonin from the synaptic cleft, thereby increasing the concentration of serotonin available to bind to postsynaptic receptors. This enhancement of serotonergic neurotransmission is widely believed to underpin its efficacy in treating various mood and anxiety disorders. Over time, chronic blockade of serotonin reuptake leads to complex adaptive changes in serotonergic receptor sensitivity and signaling pathways, which are thought to contribute to the delayed onset of full therapeutic benefits, typically manifesting over several weeks. Paroxetine possesses minimal affinity for other neurotransmitter receptors, such as muscarinic cholinergic, alpha1, alpha2, and beta-adrenergic, dopaminergic (D2), and histamine (H1) receptors. This selectivity largely accounts for its improved side effect profile compared to older antidepressant classes like tricyclic antidepressants, which often exhibit broader receptor binding and associated anticholinergic or cardiovascular adverse effects. However, paroxetine does exhibit some mild anticholinergic activity, which may contribute to side effects such as dry mouth or constipation in some individuals. The controlled-release formulation (e.g., Paraxyl CR 12.5mg) is designed to provide a more gradual and sustained release of the active compound, aiming to maintain more stable plasma concentrations and potentially minimize peak-related side effects like nausea often seen with immediate-release versions, while ensuring continuous serotonergic modulation.